Dual inhibition, newer paradigms for cholesterol lowering

American Journal of Therapeutics

Volumn 17, Issue 4, 2010, Pages

  Katragadda, Srikanth ^a   Rai, Fasi ^a   Arora, Rohit ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

coronary heart disease; ezetimibe; LDL cholesterol; statins

Indexed keywords

AMIODARONE; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CLARITHROMYCIN; CYCLOSPORIN; DANAZOL; ERYTHROMYCIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NEFAZODONE; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TELITHROMYCIN; TRIACYLGLYCEROL; VERAPAMIL; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTERIAL STIFFNESS; ARTHRALGIA; ATHEROMA; ATHEROSCLEROSIS; BACKACHE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; FLUSHING; GALLBLADDER DISEASE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIVER DISEASE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; MUSCLE CRAMP; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS DISEASE; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; BLOOD; COMPLICATION; CORONARY DISEASE; DRUG COMBINATION; DRUG INTERACTION; FEMALE; MALE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RISK FACTOR;

ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; CORONARY DISEASE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 77954969146     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31815adf85     Document Type: Review

References (46)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics: 2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
2. Kreisberg RA, Oberman A. Lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab. 2002;87:423-437.
3. NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002:106: 3143-3421.
4. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association; for the Coordinating Committee of the National Cholesterol Education Program. Adult treatment panel III guidelines. Circulation. 2004;110:227-239.
5. Davidson MH, Maki KC, Pearson TA, et al. Results of National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the NCEP writing group recommendations. Am J Cardiol. 2005;96: 556-563.
6. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
7. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372. (Pubitemid 43947981)
8. Chernobelskey A, Ashen MD, Blumenthal RS, et al. Highdensity lipoprotein cholesterol: a potential therapeutic target for prevention of coronary artery disease. Prev Cardiol. 2007;10:26-30.
9. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-1232.
10. Ballantyne CM, Nambi V. Apolipoprotein A-I and highdensity lipoprotein. Am Coll Cardiol. 2004;44:1436-1438.
11. Tall AR, Wang N. Tangier disease as a test of the reverse cholesterol transport hypothesis. J Clin Invest. 2000;106: 1205-1207.
12. National Institutes of Health. National Cholesterol Education Program. NIH publication no. 01-3670. Bethesda, MD: National Institutes of Health, May 2001.
13. Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. Circulation. 2004:109(Suppl III); 8-14.
14. McLeod RS, LeBlanc AM, Langille MA. Conjugated linoleic acids, atherosclerosis, and hepatic very-low-density lipoprotein metabolism. Am J Clin Nutrition. 2004:79(Suppl): 11698-11748.
15. Botham KM, Bravo E, Elliott J, et al. Direct interaction of dietary lipids carried in chylomicron remnants with cells of the artery wall: implications for atherosclerosis development. Curr Pharm Des. 2005;11:3681-3695.
16. Kawakami A, Yoshida M. Remnant lipoproteins and atherogenesis. J Atheroscler Thromb. 2005;12:73-76.
17. Groot PHE, van Stiphout WAHJ, Krauss XH, et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Atheroscler Thromb. 1991;11:653-662.
18. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000;35:1-10.
19. Watts GF, Dimmitt SB. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol. 1999;10:561-574.
20. Miller M. Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc. 2003;78:735-742.
21. Altmann SW, Davis HR Jr, Zhu L-J, et al. Niemann-Pick C1-like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201-1204.
22. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets investigators. N Engl J Med. 2005;352:1425-1435.
23. Pederson TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445.
24. Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID investigators. JAMA. 2006;295:1556-1565 (E-pub 2006 Mar 13).
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002:360:7-22.
26. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. J Am Heart J. 2005;149:464-473.
27. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004;148:447-455.
28. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipidaltering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006;22:2041-2053.
29. Masana L, Mata P, Gagné C, et al. Ezetimibe Study Group. Long-term safety and tolerability profiles and lipidmodifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther. 2005;27:174-184.
30. Goldberg AC, Sapre A, Liu J, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79:620-629.
31. Pearson TA, Denke MA, Mcbride PE, et al. A communitybased, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-On To Statin For Effectiveness (EASE) Trial. Mayo Clin Proc. 2005;80:587-595.
32. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/ simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc. 2006;81:1579-1588.
33. Kohnle M, Pietruck F, Kribben A, et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant. 2006;6:205-208.
34. Landray M, Baigent C, Leaper C, et al. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006;47:385-395.
35. Gagné C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469-2475.
36. Rodney RA, Sugimoto D, Wagman B, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. J Natl Med Assoc. 2006;98:772-778.
37. Bennett S, Sager P, Lipka L, et al. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. J Womens Health (Larchmt). 2004;13:1101-1107.
38. Ezetimibe Study Group. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging. 2004;21: 1025-1032.
39. Efrati S, Averbukh M, Dishy V, et al. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol. 2007;63:113-121.
40. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for-pleiotropic- functions of statin therapy. Eur Heart J. 2006;27:1182-1190 (E-pub 2006 Apr 18).
41. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111: 2356-2363 (E-pub 2005 May 2).
42. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007;192: 432-437 (E-pub 2007 Jan 19).
43. ADVOCATE Trial Group. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin [the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation (ADVOCATE)]. Am J Cardiol. 2003;91:667-672.
44. Ezetimibe, Simvastatin Plus Fenofibrate Study Group. Efficacy and safety of the coadministration of ezetimibe/ simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J. 2007;153:335(e1-8).
45. Berthold HK, Naini A, Di Mauro S, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Safety. 2006;29:703-712.
46. Davidson MH, Maccubbin D, Stepanavage M, et al. Striated muscle safety of ezetimibe/simvastatin (Vytorin). AmJ Cardiol. 2006;15(97):223-228 (E-pub 2005 Nov 21).